Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 123 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
123 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with select advanced/metastatic solid tumors after standard therapy (melanoma, cSCC, Merkel cell, NSCLC, HNSCC, gastric/GEJ, RCC, HGSOC, TNBC) receive AZD6750, an investigational CD8-guided IL-2 designed to preferentially activate CD8+ T cells; a separate module enrolls NSCLC (including 1L PD-L1 ≥1%) to receive AZD6750 plus rilvegostomig, a bispecific PD-1/TIGIT antibody. Key exclusions include uncontrolled CNS disease, active autoimmune disease, prior severe I/O toxicities, and in the NSCLC module prior anti-TIGIT or targetable driver-positive 1L disease.
ClinicalTrials.gov ID: NCT07115043
TrialFetch AI summary: Adults with metastatic or inoperable somatostatin receptor–positive tumors (GI NETs, pheochromocytoma/paraganglioma, small cell lung, renal cell, and select head/neck cancers) confirmed by SSTR PET receive [212Pb]VMT-Alpha-NET, an SSTR2-targeted alpha-emitting radioligand (212Pb→212Bi) given IV every 8 weeks for up to 4 cycles, with an optional [203Pb] imaging/dosimetry lead-in. Excludes prior systemic radioligand therapy; allows treated/stable or asymptomatic CNS mets and requires adequate organ function.
ClinicalTrials.gov ID: NCT06479811
TrialFetch AI summary: Adults with locally advanced/metastatic solid tumors—emphasizing urothelial carcinoma—harboring actionable FGFR3 alterations receive the selective FGFR3 inhibitor LOXO-435 (LY3866288) as monotherapy or combined with pembrolizumab ± enfortumab vedotin. Cohorts include FGFR inhibitor–naïve, post–FGFR inhibitor, and first-line mUC settings; key exclusions include uncontrolled CNS disease and significant ocular/cardiac risks.
ClinicalTrials.gov ID: NCT05614739
TrialFetch AI summary: Treatment‑naïve adults with locally advanced or metastatic clear‑cell RCC (ECOG 0–1), including those with controlled, non–life‑threatening brain metastases, receive triplet therapy with 177Lu‑girentuximab (TLX250; CAIX‑targeted radiolabeled mAb delivering beta radiation), nivolumab (PD‑1 inhibitor), and cabozantinib (VEGFR/MET/AXL TKI). Key exclusions include prior systemic therapy for metastatic RCC, active autoimmune disease requiring therapy, recent major cardiovascular events, significant GI/fistula risk, uncontrolled hypertension, strong CYP3A4 modulators, and recent major surgery.
ClinicalTrials.gov ID: NCT05663710
TrialFetch AI summary: Adults with unresectable or metastatic clear cell RCC (± sarcomatoid) that recurred during adjuvant anti–PD-(L)1 or within 24 months after completion, without prior VEGF/TKI or HIF-2α therapy, receive oral zanzalintinib (VEGFR2/MET/TAM multi-TKI) plus belzutifan (HIF‑2α inhibitor). Open-label, nonrandomized cohorts explore two zanzalintinib dose levels to assess safety and preliminary efficacy (ORR by BICR).
ClinicalTrials.gov ID: NCT07049926
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors and evaluates the safety and therapeutic activity of GI-101, a bispecific fusion protein targeting CTLA-4 and the IL-2 pathway, as a single agent and in combination with pembrolizumab, lenvatinib, or radiotherapy.
ClinicalTrials.gov ID: NCT04977453
TrialFetch AI summary: This trial investigates GSK4381562, a monoclonal antibody targeting PVRIG to enhance NK and T cell activation, as monotherapy and in combination with anticancer agents such as dostarlimab, belrestotug, nelistotug, and GSK5764227 in patients with advanced solid tumors who lack standard treatment options. Eligible participants have locally recurrent or metastatic solid tumors, have progressed after standard therapies, and possess an ECOG performance status of 0-1 with adequate organ function.
ClinicalTrials.gov ID: NCT05277051
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including specific expansion cohorts for RCC, NSCLC, and PD-L1-negative NSCLC—who have progressed after or cannot tolerate standard therapies or are treatment naïve for metastatic disease without actionable mutations. Patients receive STK-012, an engineered IL-2 partial agonist that selectively stimulates CD25+ T cells with reduced toxicity risk, as monotherapy or in combination with pembrolizumab, and in NSCLC, with pembrolizumab plus pemetrexed and carboplatin.
ClinicalTrials.gov ID: NCT05098132
TrialFetch AI summary: Adult patients with unresectable locally advanced or metastatic solid tumors (including melanoma, renal cell carcinoma, or PD-L1-positive NSCLC) who have progressed after or are ineligible for standard therapies receive AU-007, a novel monoclonal antibody that redirects IL-2 activity toward effector T and NK cells by blocking IL-2Rα, as monotherapy or in combination with recombinant IL-2 and/or checkpoint inhibitors. Patients must have adequate organ function, resolved prior immunotherapy toxicity, and measurable or evaluable disease.
ClinicalTrials.gov ID: NCT05267626
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic renal cell carcinoma, melanoma, cutaneous squamous cell carcinoma, or PD-L1-positive non-small cell lung cancer who are relapsed/refractory to standard therapy or lack standard options, have ECOG 0/1, and meet organ function criteria; exclusions include prior IL-2, active autoimmune disease, and symptomatic brain metastases requiring steroids. Treatments include WTX-124, a conditionally activated IL-2 prodrug that targets the tumor microenvironment, as monotherapy or in combination with pembrolizumab (anti-PD-1).
ClinicalTrials.gov ID: NCT05479812